Literature DB >> 11807604

Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics.

Hans-Jürgen Wester1, Margret Schottelius, Klemens Scheidhauer, Jean-Claude Reubi, Ingo Wolf, Markus Schwaiger.   

Abstract

Although somatostatin-based peptide receptor imaging (sst-PRI) and peptide receptor radiotherapy (sst-PRRT) of human endocrine tumours and their metastases has become a valuable method, the experience with radiohalogenated sst-directed peptides has so far been disappointing. To extend the broad spectrum of radiohalogens with suitable radionuclide properties for sst-PRI and PRRT, new strategies in ligand development are required. The major drawbacks to be overcome include fast hepatic uptake, high abdominal background activity and low tumour uptake. Recently we introduced radiolabelled glycated octreotides as a new series of sst-binding radiotracers with excellent physicochemical characteristics. In this study we compared [(125)I]Tyr(3)-octreotide ([(125)I]TOC, ( 1)), [(125)I]Tyr(3)-octreotate ([(125)I]TOCA, ( 2)) and a carbohydrated octreotide derivative, maltotriose-[(125)I]Tyr(3)-octreotate ([(125)I]Mtr-TOCA, ( 3)) to evaluate the effect of single C-terminal oxidation and simultaneous N-terminal carbohydration. The biodistribution was compared in nude mice bearing AR42J tumour xenografts. Compared with ( 1), activity uptake of ( 2) and ( 3) at 1 h was decreased in intestine [36% ( 2), 72% ( 3)], liver [62% ( 2), 79% ( 3)] and kidney [34% ( 2), 41% ( 3)], respectively. Blood clearance was fast for all compounds investigated. Using ( 1) as reference, tumour uptake of ( 2) and ( 3) was 3.8- and 4.3-fold higher at 1 h p.i. At 1 h the tumour-to-blood ratio of ( 3) was 28.2+/-7.3, and the tumour-to-muscle ratio, 147+/-48. Specificity of tumour uptake was demonstrated in AR42J tumour-bearing mice by pretreatment with 0.8 mg TOC/kg 5 min prior to injection of ( 3). In cells transfected with sst1-sst5, the binding profile of I-Mtr-TOCA revealed a very high affinity and selectivity for sst2. In a first scintigraphic [(123)I]Mtr-TOCA study of a patient with a carcinoid of the small intestine with known peritoneal carcinomatosis and a solitary liver metastasis, all tumour tissues, including the liver metastasis, were well defined and clearly visible as soon as 30 min p.i. Based on these encouraging findings we conclude that carbohydration is a powerful strategy for the development of new radiolabelled sst-binding peptides and may represent a general method to improve pharmacokinetics of other peptide radioligands. [(123)I]Mtr-TOCA is a very promising new candidate for sst-directed PRI.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11807604     DOI: 10.1007/s00259-001-0669-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  9 in total

1.  [123I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [111In]octreotide.

Authors:  Alexander Stahl; Günther Meisetschläger; Margret Schottelius; Kjerstin Bruus-Jensen; Ingo Wolf; Klemens Scheidhauer; Markus Schwaiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-09       Impact factor: 9.236

Review 2.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

Review 3.  FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions.

Authors:  K Scheidhauer; C Walter; M D Seemann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-06       Impact factor: 9.236

4.  Imaging integrin alpha-v-beta-3 expression in tumors with an 18F-labeled dimeric RGD peptide.

Authors:  Ingrid Dijkgraaf; Samantha Y A Terry; William J McBride; David M Goldenberg; Peter Laverman; Gerben M Franssen; Wim J G Oyen; Otto C Boerman
Journal:  Contrast Media Mol Imaging       Date:  2013 May-Jun       Impact factor: 3.161

5.  PET/CT with Gluc-Lys-([(18)F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions.

Authors:  Hinrich Wieder; Ambros J Beer; Thorsten Poethko; Guenther Meisetschlaeger; Hans-Juergen Wester; Ernst Rummeny; Markus Schwaiger; Alexander R Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-03       Impact factor: 9.236

6.  Proof of principle for the use of 11C-labelled peptides in tumour diagnosis with PET.

Authors:  G Henriksen; M Schottelius; T Poethko; A Hauser; I Wolf; M Schwaiger; Hans-Jürgen Wester
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-10       Impact factor: 9.236

7.  Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD.

Authors:  Roland Haubner; Wolfgang A Weber; Ambros J Beer; Eugenija Vabuliene; Daniel Reim; Mario Sarbia; Karl-Friedrich Becker; Michael Goebel; Rüdiger Hein; Hans-Jürgen Wester; Horst Kessler; Markus Schwaiger
Journal:  PLoS Med       Date:  2005-03-29       Impact factor: 11.069

8.  Positron detection for the intraoperative localisation of cancer deposits.

Authors:  Morand Piert; Maria Burian; Günther Meisetschläger; Hubert J Stein; Sibylle Ziegler; Jörg Nährig; Maria Picchio; Andreas Buck; Joerg R Siewert; Markus Schwaiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-12       Impact factor: 9.236

9.  Effect of Carbohydration on the Theranostic Tracer PSMA I&T.

Authors:  Alexander Schmidt; Martina Wirtz; Stefanie Felicitas Färber; Theresa Osl; Roswitha Beck; Margret Schottelius; Markus Schwaiger; Hans-Jürgen Wester
Journal:  ACS Omega       Date:  2018-07-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.